The toxic financing is the result of the language in the notes and has nothing to do with the trading platform. This stock has gotten so much energy on the runup because of promotion based on what people don't understand about this method patent and trading platform. Blackstar can't even get their own shares trading on the platform and you will be hard pressed to find another stock where the toxic financers have fleeced retail this badly.
Blackstar started 2023 with 546,495,214 and during the first nine months of 2023 the more than doubled the share count with an additional 698 million shares to settle only $116K of debt. Most of those shares priced at an average of $0.00017 a share were issued in Q2 and Q3 of 2023. They held back the shares for GS Capital conversions which resulted the lawsuit that promises to serve up hundreds of millions of new shares with a conversion price of $0.00013. The approval of the method patent changes none of this. In fact the method patent based on Amazons product appears to be very weak to me.
What the patent does if it gives Blackstar the right to spend money trying to defend it if the SEC ever allows it and if anyone was interested in using it. Two infomercials and all the CEO has in terms of new information is that they want to plug "corporate governance" and "capital fund raising" into this method patent template. What Blackstar needs is a narrative from which to sell shares. They have zero actual business, zero revenue, and zero full time employees. This has been the case for years.